Tofacitinib for treating juvenile idiopathic arthritis: Final appraisal document
In DRAFT guidance, NICE recommends tofacitinib as an option for treating active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in people 2 years and older, if they meet the stated criteria.
Source:
National Institute for Health and Care Excellence
SPS commentary:
The DRAFT guidance recommends use in this population if their condition has responded inadequately to previous treatment with DMARDs, and only if a TNF-alpha inhibitor is not suitable or does not control the condition well enough, and the company provides tofacitinib according to the commercial arrangement.
Tofacitinib can be used with methotrexate, or as monotherapy when methotrexate is not tolerated or if continued treatment with methotrexate is inappropriate.
If tofacitinib is one of a range of treatments considered suitable by patients, or their parents or carers, and their clinicians, the least expensive should be chosen (taking into account administration costs and commercial arrangements).